pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharma International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State, Breas
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity
Phase 1 · other · Adults Living with Overweight and Obesity
A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity for Adults Living with Overweight and Obesity is a Phase 1 program (other) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Internal code WVE-007-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elan Pharma International
- Phase
- Phase 1
- Modality
- other
- Indication
- Adults Living with Overweight and Obesity
- Status
- active
- Trials
- 1